In the BioHarmony Drug Report Database

"Preview" Icon

Sunitinib

Sutent (sunitinib) is a small molecule pharmaceutical. Sunitinib was first approved as Sutent on 2006-01-26. It is used to treat gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, and renal cell carcinoma in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors, neuroendocrine tumors, and renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 3, platelet-derived growth factor receptor beta, and mast/stem cell growth factor receptor Kit. In addition, it is known to target fibroblast growth factor receptor 1, receptor-type tyrosine-protein kinase FLT3, vascular endothelial growth factor receptor 2, proto-oncogene tyrosine-protein kinase receptor Ret, and platelet-derived growth factor receptor alpha. Sutent’s patent is valid until 2021-02-15 (FDA).

 

Trade Name

 

Sutent
 

Common Name

 

sunitinib
 

ChEMBL ID

 

CHEMBL535
 

Indication

 

gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, renal cell carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Sunitinib structure rendering